Figure 3.
Incidence of ≥Gr3 NC AEs based on response and disease burden. (A) Dot plot of ≥Gr3 NC AEs in patients with complete response (CR) compared with that in those without CR (no CR). (B) Dot plot of ≥Gr3 NC AEs in patients based on both CRS and response. (C) Heat map of ≥Gr3 NC AEs based on the system in nonresponders (no CR) with CRS and without CRS. Deeper blue corresponds to greater number of events per patient. (D) Dot plot of ≥Gr3 NC AEs in patients based on baseline bone marrow disease as determined based on the percent mononuclear cells via flow cytometry: M1, <5%; M2, from 5% to 25%; M3, >25%. (E) Combined dot plots evaluating number ≥Gr3 NC AEs in patients based on baseline bone marrow disease in each of 4 response cohorts defined in panel B.

Incidence of ≥Gr3 NC AEs based on response and disease burden. (A) Dot plot of ≥Gr3 NC AEs in patients with complete response (CR) compared with that in those without CR (no CR). (B) Dot plot of ≥Gr3 NC AEs in patients based on both CRS and response. (C) Heat map of ≥Gr3 NC AEs based on the system in nonresponders (no CR) with CRS and without CRS. Deeper blue corresponds to greater number of events per patient. (D) Dot plot of ≥Gr3 NC AEs in patients based on baseline bone marrow disease as determined based on the percent mononuclear cells via flow cytometry: M1, <5%; M2, from 5% to 25%; M3, >25%. (E) Combined dot plots evaluating number ≥Gr3 NC AEs in patients based on baseline bone marrow disease in each of 4 response cohorts defined in panel B.

Close Modal

or Create an Account

Close Modal
Close Modal